Cancer cells establish replicative immortality by activating a telomere-maintenance
mechanism (TMM), be it telomerase or the alternative lengthening of telomeres (ALT) …

Over the past decade, melanoma has led the field in new cancer treatments, with impressive
gains in on-treatment survival but more modest improvements in overall survival. Melanoma …

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

A variety of species of bacteria are known to colonize human tumours,,,,,,,,,–, proliferate
within them and modulate immune function, which ultimately affects the survival of patients …

Most cancers exhibit aneuploidy, but its functional significance in tumor development is
controversial. Here, we describe ReDACT (Restoring Disomy in Aneuploid cells using …

This ESMO Clinical Practice Guidelines provide updated recommendations on management
of cutaneous melanoma (diagnosis, treatment and follow-up), compiled by a …

Immune-checkpoint blockade (ICB) has demonstrated efficacy in many tumor types, but
predictors of responsiveness to anti-PD1 ICB are incompletely characterized. In this study …

Somatic mutations in cancer genomes are caused by multiple mutational processes, each of
which generates a characteristic mutational signature. Here, as part of the Pan-Cancer …

Background Nivolumab monotherapy and combination nivolumab plus ipilimumab increase
proportions of patients achieving a response and survival versus ipilimumab in patients with …

Cancer is driven by genetic change, and the advent of massively parallel sequencing has
enabled systematic documentation of this variation at the whole-genome scale,–. Here we …